healthcare

healthcare Articles

Genome editing company LogicBio Therapeutics expects to price more than 5 million shares for an initial public offering valued up to almost $93 million.
Proteostasis Therapeutics shares absolutely exploded on Thursday after the company announced positive preliminary results from its early-stage cystic fibrosis trial.
Endocyte shares were up sharply early Thursday after it was announced that the company would be acquired.
Synthetic biology company Twist Bioscience expects to price 5 million shares for an initial public offering valued up to more than $103 million.
Merck shares were up handily on Tuesday after the company announced a key update from the FDA on its Lynparza for the treatment of pancreatic cancer.
UnitedHealth released better-than-expected third-quarter financial results before the markets opened on Tuesday.
Johnson & Johnson reported better-than-expected third-quarter financial results before the markets opened on Thursday.
UnitedHealth is scheduled to report its second-quarter financial results before the markets open on Tuesday.
Johnson & Johnson is scheduled to report its third-quarter financial results early Tuesday, and analysts expect solid growth on the top and bottom lines.
Tetraphase Pharmaceuticals shares were up handily on Friday after the company announced the U.S. commercial launch of Xerava (eravacycline) for the treatment of complicated intra-abdominal infections.
Corium shares jumped on Friday after the company announced that it entered into a definitive merger agreement under which Gurnet Point Capital will acquire Corium.
Compugen shares pushed higher on Thursday after it was announced that Bristol-Myers Squibb will make a $12 million equity investment as part of its collaboration on a cancer trial.
CRISPR Therapeutics shares made a handy gain on Thursday after the company announced a key FDA decision concerning its collaboration with Vertex Pharmaceuticals.
Ionis Pharmaceuticals shares were relatively flat on Wednesday after the company announced a new collaboration with Roche to develop IONIS-FB-LRx for the treatment of complement-mediated diseases.
AcelRx shares made a solid gain on Wednesday despite a less-than-favorable update from the FDA. However, there is a vote for approval on Friday. and that seems to be what investors are optimistic...